Regular Treatment for Syphilis

PreclinicalSmall molecule

OOttawa Hospital Research Institute

Regular Treatment for Syphilis is one of 7 small molecule programs targeting Syphilis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

SyphilisActive, not recruiting

SyphilisPreclinical

Active, not recruiting

Competition

Competitive Landscape

8 competitors in Syphilis

#DrugCompanyPhaseTrials

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

5 2

Rocephin

CConrado Roberto Hoffmann Filho

Approved

1 3

Amoxil

GGlobal Antibiotics Research and Development Partnership

Phase 3

1 4

Suprax

WWyeth-Lederle Vaccines

Approved

2 5

Doxycycline for 14 Days

UUniversity of Washington

Ceftriaxone Sodium

1 7

Regular Treatment for Syphilis

OOttawa Hospital Research Institute

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Syphilis1 trial

Penicillin Therapeutic Drug Monitoring in the Treatment of Infectious Syphilis.

Terminated·OOttawa Hospital Research Institute··NCT01540227·25 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Regular Treatment for Syphilis. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Regular Treatment for Syphilis compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Regular Treatment for Syphilis. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ottawa Hospital Research Institute company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: OOttawa Hospital Research Institute

Regular Treatment for Syphilis

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Syphilis1 trial

References

Drug Info

Quick Facts

Related News